May 26, 2017
1 min read

Lieberman receives NIH grant for research on gene therapy for repair of bone injuries

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Jay R. Lieberman, MD, chair and professor of orthopedic surgery at Keck School of Medicine of the University of Southern California received a 5-year, $2.2 million grant from the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases for gene therapy research to enhance repair of extensive bone injuries, according to a press release.

According to the release, Lieberman’s research will seek to genetically manipulate human bone marrow cells to overexpress bone morphogenetic protein (BMP). The study will reportedly determine the efficacy and safety of gene therapy. In addition, Lieberman will attempt to establish a cellular dose of genetically manipulated cells that can be scaled up and potentially be used in humans.

Jay R. Lieberman

“There are a number of bone injuries that are difficult to repair and lack satisfactory solutions,” Lieberman said in the press release. “My goal with this grant is to determine whether genetically modifying human bone marrow cells to overproduce BMP will help heal large bone defects in an animal model and, ultimately, provide a better alternative for repairs in humans.”